Curis (NASDAQ:CRIS) Earns “Buy” Rating from HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $20.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 406.33% from the company’s current price.

Curis Stock Down 0.8 %

Shares of CRIS stock opened at $3.95 on Friday. Curis has a 12 month low of $3.51 and a 12 month high of $17.49. The company has a market cap of $23.62 million, a PE ratio of -0.51 and a beta of 3.35. The business’s 50 day moving average is $5.01 and its two-hundred day moving average is $7.12.

Institutional Investors Weigh In On Curis

A number of hedge funds have recently bought and sold shares of the company. Focused Wealth Management Inc increased its stake in shares of Curis by 63.1% in the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after buying an additional 96,256 shares during the last quarter. CM Management LLC boosted its position in shares of Curis by 380.0% in the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.